tradmap

NAUT Nautilus Biotechnology, Inc.

$2.37 -13.50%

Data as of close

Healthcare · Laboratory Analytical Instruments

Nautilus Biotechnology, Inc. (NAUT) is a healthcare company in the Laboratory Analytical Instruments industry, with a market capitalization of $302 million. Shares last traded at $2.37, 44.7% below their 52-week high. Over the past year the stock is up 69.3%.

Market Cap
$302M
Shares Out
127.4M
EPS (TTM)
-$0.46
P/E (TTM)*
—
P/S Ratio
—
P/B Ratio
2.59
Dividend / Share
—
Dividend Yield
—
52-Week High
$4.29
52-Week Low
$0.85
Volume (venue)
221,162
Avg Vol (3m, venue)
176,937.016

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+1.72%
1M
+5.80%
3M
+139.93%
6M
-18.28%
YTD
+22.16%
1Y
+69.29%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
51.41
SMA (50)
$1.63
SMA (200)
$2.12
Price vs SMA50
+45.50%
Price vs SMA200
+11.61%
ATR (14)
$0.44

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
—
Net Income
-$59M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-50.3%
Return on Assets
-39.3%
Current Ratio
9.25
Debt / Equity
0.28
Revenue Growth (YoY)
—

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 -$0.12 2026-10-27
Q2 2026 -$0.11 2026-07-28
Q1 2026 -$0.12 2026-04-28
Q4 2025 (derived) -$0.11 2026-02-26
FY 2025 -$0.47 2026-02-26
Q3 2025 -$0.11 2025-10-28

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Laboratory Analytical Instruments peers

NAUT vs 14 industry peers (Laboratory Analytical Instruments), by market cap. Data as of close

1–14 of 14
AAgilent Technologies$48.5B33.686.5819.5%-1.62%
WATWaters Corporation$44.2B68.719.5113.8%-2.86%
ILMNIllumina, Inc.$34.2B38.267.5519.7%-4.10%
MTDMettler Toledo$33.6B37.148.1421.9%+0.17%
RVTYRevvity$16.9B71.265.818.2%-3.38%
AVTRAvantor, Inc.$10.6B31.351.595.1%-2.86%
BIOBio-Rad Laboratories, Inc.$9.8B44.033.788.6%-1.57%
BRKRBruker Corp$8.5B—2.42-2.0%-2.48%
TXG10x Genomics, Inc.$8.0B—13.01-12.2%-12.14%
ALMRAlamar Biosciences, Inc.$2.0B———-5.48%
CTKBCytek Biosciences, Inc.$751M—3.63-32.2%-5.56%
PACBPacific Biosciences Of California, Inc.$727M———-10.34%
MASS908 Devices Inc.$421M—6.92-57.0%-9.26%
NAUTNautilus Biotechnology, Inc.$302M———-13.50%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.